ERBB2 and skin basal cell carcinoma: The label-free, non-invasive, continuous IncuCyte imaging system was used to determine dose-dependent effects of SMI-6 on the growth and survival of six BCC with different properties: BT474 (luminal B, ER/PR/Her2+), MCF7 (luminal A, ER/PR+, Her2−), T47D (luminal A, ER/PR+, Her2−), MDA-MB-231 (Claudine low, triple negative), ZR75-1 (luminal B, ER/PR/HER2+), and MDA-MB-468 (basal, triple negative).